Trial Profile
A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary) ; Budesonide/formoterol; Salbutamol; Salmeterol/fluticasone propionate
- Indications Allergic asthma
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Biomabs Pharmaceuticals
- 08 Oct 2021 Status changed from recruiting to completed.
- 17 Mar 2020 Planned End Date changed from 1 Dec 2019 to 30 Nov 2020.
- 17 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 30 Nov 2020.